NO20073868L - Levende attenuert rotavirus vaksine for oral administrering - Google Patents

Levende attenuert rotavirus vaksine for oral administrering

Info

Publication number
NO20073868L
NO20073868L NO20073868A NO20073868A NO20073868L NO 20073868 L NO20073868 L NO 20073868L NO 20073868 A NO20073868 A NO 20073868A NO 20073868 A NO20073868 A NO 20073868A NO 20073868 L NO20073868 L NO 20073868L
Authority
NO
Norway
Prior art keywords
oral administration
live attenuated
rotavirus
rotavirus vaccine
attenuated rotavirus
Prior art date
Application number
NO20073868A
Other languages
English (en)
Other versions
NO341789B1 (no
Inventor
Vincent Vande Velde
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34385675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073868(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20073868L publication Critical patent/NO20073868L/no
Publication of NO341789B1 publication Critical patent/NO341789B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen tilveiebringer flytende rotavirus-formuleringer som er egnet for oral administrering til menneskebarn. Spesielt tilveiebringer oppfinnelsen farmasøytiske preparater og vaksiner, omfattende et rotavirus-antigen, et sukker og et karboksylat hvor nevnte formulering har en pH på mellom pH 5,0 og pH 8,0 og omfatter intet fosfat eller mindre enn 5 mM fosfat. Oppfinnelsen tilveiebringer også metoder for fremstilling av nevnte rotavirus-formuleringer og anvendelse derav for forebygging eller behandling av rotavirus-assosierte sykdommer hos mennesker.
NO20073868A 2005-02-17 2007-07-24 Flytende rotavirus immunogent preparat og anvendelse og fremstilling derav. NO341789B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0503337.8A GB0503337D0 (en) 2005-02-17 2005-02-17 Compositions
PCT/EP2006/001442 WO2006087205A1 (en) 2005-02-17 2006-02-15 Live attenuated rotavirus vaccine for oral administration

Publications (2)

Publication Number Publication Date
NO20073868L true NO20073868L (no) 2007-11-15
NO341789B1 NO341789B1 (no) 2018-01-22

Family

ID=34385675

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073868A NO341789B1 (no) 2005-02-17 2007-07-24 Flytende rotavirus immunogent preparat og anvendelse og fremstilling derav.

Country Status (32)

Country Link
US (2) US8192747B2 (no)
EP (2) EP2322211A1 (no)
JP (1) JP5118977B2 (no)
KR (1) KR101319846B1 (no)
CN (2) CN103357005A (no)
AP (1) AP2692A (no)
AR (1) AR053680A1 (no)
AT (1) ATE516044T1 (no)
AU (1) AU2006215761B2 (no)
BR (1) BRPI0608877B8 (no)
CA (1) CA2598290C (no)
CY (1) CY1111916T1 (no)
DK (1) DK1863526T3 (no)
EA (1) EA012046B1 (no)
ES (1) ES2369246T3 (no)
GB (1) GB0503337D0 (no)
HR (1) HRP20110668T1 (no)
IL (1) IL184802A0 (no)
MA (1) MA29321B1 (no)
MX (1) MX2007010075A (no)
MY (1) MY145790A (no)
NO (1) NO341789B1 (no)
NZ (1) NZ560314A (no)
PE (1) PE20061094A1 (no)
PL (1) PL1863526T3 (no)
PT (1) PT1863526E (no)
SI (1) SI1863526T1 (no)
TW (1) TWI358303B (no)
UA (1) UA91044C2 (no)
UY (1) UY29377A1 (no)
WO (1) WO2006087205A1 (no)
ZA (1) ZA200706668B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008014391A (es) * 2006-05-12 2009-03-06 Bharat Biotech Int Ltd Una composicion util como vacuna.
WO2009042202A2 (en) * 2007-09-25 2009-04-02 Aridis Pharmaceuticals Formulations for preservation of rota virus
EP2236617A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
EP3427750A1 (en) 2009-05-12 2019-01-16 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services New human rotavirus strains and vaccines
CN101972475B (zh) * 2010-04-12 2014-04-09 李建平 一种细菌多糖-蛋白结合疫苗及其制备方法
CN101863966B (zh) * 2010-05-21 2012-10-03 中国人民解放军第三军医大学 抗轮状病毒药物作用靶标及其构建方法和应用方法
ES2639888T3 (es) 2010-09-24 2017-10-30 University Of Florida Research Foundation, Inc. Materiales y procedimientos para mejorar la función gastrointestinal
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
WO2012103472A1 (en) * 2011-01-28 2012-08-02 Brian Pulliam Granularized particular thermostable rotovirus vaccine preparation
JP2014512410A (ja) * 2011-04-28 2014-05-22 インターナショナル メディカ ファウンデーション 液体ワクチン調製物
CN102349932B (zh) * 2011-10-12 2012-12-26 刘壮华 一种治疗息肉的药物制剂
WO2013105105A2 (en) * 2012-01-13 2013-07-18 Serum Institute Of India Ltd. Novel viral vaccine compositions and methods for preparing such vaccines
KR102262179B1 (ko) * 2012-02-08 2021-06-07 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 설사를 치료하기 위한 물질 및 방법
US9827303B2 (en) 2012-03-05 2017-11-28 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Methods and compositions for stabilizing dried biological materials
WO2013160913A1 (en) 2012-04-23 2013-10-31 Bharat Biotech International Limited Rotavirus vaccine compositions and process for preparing the same
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
EP3427730B1 (en) 2013-03-11 2024-07-10 University of Florida Research Foundation, Inc. Materials and methods for improving lung function
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) * 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
CN103316335B (zh) * 2013-05-31 2014-11-12 北京科兴生物制品有限公司 一种适于口服的脊髓灰质炎病毒疫苗
CN103316336B (zh) * 2013-05-31 2015-01-28 北京科兴中维生物技术有限公司 一种适于口服的轮状病毒疫苗
RU2662558C2 (ru) * 2013-07-19 2018-07-26 Хексаль Аг Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
US20160206728A1 (en) * 2013-10-03 2016-07-21 Nitto Denko Corporation Dried influenza vaccine preparation and method of producing the same
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CN113730564A (zh) * 2014-12-08 2021-12-03 武汉生物制品研究所有限责任公司 口服六价重配轮状病毒活疫苗
US10548970B2 (en) 2015-10-05 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rotavirus G9P[6] strain and use as a vaccine
CA3006069A1 (en) * 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Thermally stable rotavirus vaccine formulations and methods of use thereof
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
WO2019201894A1 (en) * 2018-04-16 2019-10-24 Merck Patent Gmbh Additives for protein formulations to improve thermal stability
CN110946871A (zh) * 2019-12-12 2020-04-03 浙江华康药业股份有限公司 槐糖在制备预防和治疗肥胖产品中的应用及对应产品
CN115531364B (zh) * 2021-06-30 2024-02-23 中国科学技术大学 预防或治疗轮状病毒感染的微生物代谢物制剂及其用途
CN113994925B (zh) * 2021-12-30 2022-04-26 北京赛尔富森生物科技有限公司 一种轮状病毒攻毒动物模型及其建立方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0557427B1 (en) 1990-11-16 1998-08-26 Children's Hospital Medical Center Human rotaviruses, vaccines and methods
NZ240818A (en) * 1990-12-14 1993-08-26 Mcneil Ppc Inc Liquid sucralose concentrate compositions containing preservative, buffer and liquid
HUT67006A (en) * 1991-08-05 1995-01-30 Sterling Winthrop Inc Buffered composition containing mammalian superoxide-dismutase/polyethylene glycol coniugate
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
CZ290331B6 (cs) 1993-11-17 2002-07-17 Laboratoires Om S. A. Glukosaminové disacharidy, způsob jejich přípravy a farmaceutický prostředek
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
DE69738271T2 (de) 1996-09-26 2008-08-28 Merck & Co., Inc. Rotavirus-impfstoff
US6616931B1 (en) * 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
NZ338101A (en) 1997-04-01 2002-03-28 Corixa Corp Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6919076B1 (en) * 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
EP1089913A1 (fr) 1998-06-08 2001-04-11 SCA Emballage France Emballage a remise a plat rapide
RU2223262C2 (ru) 1998-06-30 2004-02-10 Ом Фарма Новые ацилированные псевдодипептиды, способ их получения и содержащие их фармацевтические композиции
CN100379451C (zh) * 1999-08-17 2008-04-09 史密丝克莱恩比彻姆生物有限公司 疫苗
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
AU784344B2 (en) 2000-01-28 2006-03-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions

Also Published As

Publication number Publication date
CN101300028B (zh) 2014-06-04
NO341789B1 (no) 2018-01-22
AU2006215761B2 (en) 2011-03-17
EP2322211A1 (en) 2011-05-18
KR101319846B1 (ko) 2013-10-22
PE20061094A1 (es) 2006-11-30
AR053680A1 (es) 2007-05-16
EA200701519A1 (ru) 2008-02-28
HRP20110668T1 (hr) 2011-10-31
US8192747B2 (en) 2012-06-05
AP2007004087A0 (en) 2007-08-31
MA29321B1 (fr) 2008-03-03
CA2598290C (en) 2015-08-11
CN101300028A (zh) 2008-11-05
ZA200706668B (en) 2009-07-29
WO2006087205A1 (en) 2006-08-24
EP1863526A1 (en) 2007-12-12
US8821891B2 (en) 2014-09-02
TW200640486A (en) 2006-12-01
JP5118977B2 (ja) 2013-01-16
BRPI0608877B8 (pt) 2021-05-25
MX2007010075A (es) 2008-01-16
PL1863526T3 (pl) 2011-12-30
BRPI0608877A2 (pt) 2012-07-31
SI1863526T1 (sl) 2011-11-30
CN103357005A (zh) 2013-10-23
UA91044C2 (uk) 2010-06-25
AP2692A (en) 2013-07-16
IL184802A0 (en) 2007-12-03
ES2369246T3 (es) 2011-11-28
US20080166372A1 (en) 2008-07-10
US20120237547A1 (en) 2012-09-20
CA2598290A1 (en) 2006-08-24
JP2008530165A (ja) 2008-08-07
EP1863526B1 (en) 2011-07-13
PT1863526E (pt) 2011-10-11
KR20070103506A (ko) 2007-10-23
NZ560314A (en) 2011-02-25
BRPI0608877B1 (pt) 2021-02-09
CY1111916T1 (el) 2015-11-04
EA012046B1 (ru) 2009-08-28
GB0503337D0 (en) 2005-03-23
DK1863526T3 (da) 2011-10-24
TWI358303B (en) 2012-02-21
UY29377A1 (es) 2006-10-02
ATE516044T1 (de) 2011-07-15
AU2006215761A1 (en) 2006-08-24
MY145790A (en) 2012-04-30

Similar Documents

Publication Publication Date Title
NO20073868L (no) Levende attenuert rotavirus vaksine for oral administrering
Jabbal-Gill Nasal vaccine innovation
Nissen et al. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults
Das et al. Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine
US20130089570A1 (en) Oral vaccine compromising an antigen and a toll-like receptor agonist
GB2451216A (en) A composition useful as a vaccine
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
ATE418324T1 (de) Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen
CO6270339A2 (es) Formulaciones de vacuna meningococica
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
WO2008054535A3 (en) Novel influenza m2 vaccines
MX351380B (es) Composiciones y metodos de vacuna de tipo ib de virus de diarrea viral de bovino.
Murugappan et al. Enhanced pulmonary immunization with aerosolized inactivated influenza vaccine containing delta inulin adjuvant
Villar-Álvarez et al. Immunosenescence, immune fitness and vaccination schedule in the adult respiratory patient
Jones et al. Protollin™: a novel adjuvant for intranasal vaccines
Kelen et al. H1N1 vaccination in pediatric renal transplant patients
KR20220047332A (ko) 치료제 효과 및 이의 투여 경로
Crothers et al. Recent advances in enterotoxin vaccine adjuvants
Young et al. Immunologic characterization of a novel inactivated nasal mumps virus vaccine adjuvanted with Protollin
US20140242112A1 (en) Novel vaccine
NO20084524L (no) Farmasoytisk sammensetning inneholdende NMB0938-protein
Weinberger Vaccines and vaccination strategies for older adults
Chong Review of approaches to caries treatment
Weinberger Effects of Ageing on the Vaccination Response
TH83579B (th) สารผสม